Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)
Multiple sclerosis is a complex, autoimmune-mediated disease of the central nervous
system characterized by inflammatory demyelination and axonal/neuronal damage. The …
system characterized by inflammatory demyelination and axonal/neuronal damage. The …
Harmonizing definitions for progression independent of relapse activity in multiple sclerosis: A systematic review
J Müller, A Cagol, J Lorscheider, C Tsagkas… - JAMA …, 2023 - jamanetwork.com
Importance Emerging evidence suggests that progression independent of relapse activity
(PIRA) is a substantial contributor to long-term disability accumulation in relapsing-remitting …
(PIRA) is a substantial contributor to long-term disability accumulation in relapsing-remitting …
Ellagic acid effects on disease severity, levels of cytokines and T-bet, RORγt, and GATA3 genes expression in multiple sclerosis patients: a multicentral-triple blind …
Background Multiple sclerosis (MS) is a chronic autoimmune disease. Ellagic acid is a
natural polyphenol and affects the fate of neurons through its anti-inflammatory and …
natural polyphenol and affects the fate of neurons through its anti-inflammatory and …
Implications of immunometabolism for smouldering MS pathology and therapy
Clinical symptom worsening in patients with multiple sclerosis (MS) is driven by
inflammation compartmentalized within the CNS, which results in chronic neuronal damage …
inflammation compartmentalized within the CNS, which results in chronic neuronal damage …
[HTML][HTML] Multiple sklerose therapie konsensus gruppe (MSTKG): positionspapier zur verlaufsmodifizierenden therapie der multiplen sklerose 2021 (White Paper)
Abstract Die Multiple Sklerose ist eine komplexe, autoimmun vermittelte Erkrankung des
zentralen Nervensystems, charakterisiert durch inflammatorische Demyelinisierung sowie …
zentralen Nervensystems, charakterisiert durch inflammatorische Demyelinisierung sowie …
[HTML][HTML] Interrogating large multiple sclerosis registries and databases: what information can be gained?
Interrogating large multiple sclerosis registries and databa... : Current Opinion in Neurology
Interrogating large multiple sclerosis registries and databases: what information can be …
Interrogating large multiple sclerosis registries and databases: what information can be …
Multiple sclerosis treatment consensus group (MSTCG): position paper on disease-modifying treatment of multiple sclerosis 2021 (white paper)
Zusammenfassung Die Multiple Sklerose ist eine komplexe, autoimmun vermittelte
Erkrankung des zentralen Nervensystems, charakterisiert durch inflammatorische …
Erkrankung des zentralen Nervensystems, charakterisiert durch inflammatorische …
Disability patterns in multiple sclerosis: A meta-analysis on RAW and PIRA in the real-world context
L Prosperini, S Ruggieri, S Haggiag… - Multiple Sclerosis …, 2024 - journals.sagepub.com
Objective: To summarize the current evidence on relapse-associated worsening (RAW) and
progression independent of relapse activity (PIRA) through a quantitative synthesis of real …
progression independent of relapse activity (PIRA) through a quantitative synthesis of real …
Continuous diffuse brain atrophy independent of relapse as a hallmark of multiple sclerosis beginning from relapsing-remitting stage
T Akaishi, J Fujimori, H Yokote, I Nakashima - Clinical Neurology and …, 2024 - Elsevier
Background Neurodegenerative changes are observed in relapsing-remitting multiple
sclerosis (RRMS) and are prominent in secondary progressive MS (SPMS). However …
sclerosis (RRMS) and are prominent in secondary progressive MS (SPMS). However …
[PDF][PDF] Utility and Implementation of a Federated Research Infrastructure to Assess Lack of Disease Stability as a Real-World Surrogate of PIRA, by Combining MS …
• Characterise the novel endpoint 'lack of disease stability', defined as deterioration of
neurological function measured by clinical and paraclinical variables collected in PwMS on …
neurological function measured by clinical and paraclinical variables collected in PwMS on …